CK-0802 clinical trials
Also written CK0801.
How each study uses CK-0802 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the CK-0802 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Cellenkos, Inc. (5)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test CK-0802.
- May 2027A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)Phase 1 · Cellenkos, Inc.
Studies
Open first, then newest update. How each study uses CK-0802 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)Not yet recruitingPhase 1/2Cellenkos, Inc.NCT07576699Written as CK0802 (Allogeneic, Cryopreserved, Cord blood-derived T-regulatory cells, cells that are not HLA matched)
- CK0801 for Treatment of Aplastic AnemiaNot yet recruitingPhase 2Cellenkos, Inc.NCT07499102Written as CK0801
- A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)Active, not recruitingPhase 1Cellenkos, Inc.NCT03773393Written as CK0801
- A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS)WithdrawnPhase 1Cellenkos, Inc.NCT03773328Written as CK0801
- REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumoniaCompletedPhase 1Cellenkos, Inc.NCT04468971Written as CK0802
Codes
What other systems call CK-0802 · ClinicalTrials.gg INT016751
- UNII (FDA) H7DFT9JF6MCK-0802One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | H7DFT9JF6M | CK-0802 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.